#Netherlands #Clinical Trials #Amsterdam #myTomorrows #Duchenne Disease

myTomorrows Connects Duchenne Patients to Critical Treatment Programs

As the awareness around Duchenne muscular dystrophy (DMD) grows, myTomorrows, a leading global health tech company, reports significant progress in connecting patients to pre-approval treatment programs. With over 600 individuals referred and nearly 300 enrolled in clinical trials, the platform is showcasing how technology can bridge the gap in rare disease treatment access.

The Role of AI in Health Tech

myTomorrows utilizes an advanced AI-powered platform that allows seamless matching of patients with clinical trials and expanded access programs (EAPs). In a field where only one-third of Duchenne patients have previously participated in trials, myTomorrows is making a notable impact by offering a solution to a fragmented referral system.

The platform ensures precise matching with up to 98% accuracy, significantly alleviating the recruitment burden on sponsors and clinics. It achieves this by analyzing vast datasets from public trial registries, thereby identifying relevant trials for patients quickly and effectively. For families affected by Duchenne muscular dystrophy, which primarily affects boys, navigating the complexities of treatment options can be an arduous journey.

Overcoming Challenges in Clinical Trials

A recent survey highlighted that 56% of physicians feel that the current clinical trial referral processes are slow and disorganized, while 72% stated that finding suitable trials is too time-consuming. These inefficiencies are especially pronounced for conditions like Duchenne, where timely referrals can greatly affect the availability of novel therapies.

By automating the clinical trial matching process, myTomorrows aids both patients and physicians in overcoming these logistical challenges. This feature streamlines access to promising treatments, which can be crucial for improving patient outcomes.

Personalized Patient Support

In addition to its innovative technology, myTomorrows pairs AI efficiency with dedicated Patient Navigators who provide personalized guidance for families facing Duchenne muscular dystrophy. In 2024 alone, the team conducted over 5,000 multilingual support calls, ensuring families are well-informed and supported in their treatment journeys. The global presence of their navigators spans multiple regions, ensuring that patients receive timely assistance regardless of their location.

The dedication of myTomorrows to improve the lives of rare disease patients is also reflected in its collaborations with various advocacy groups. The company regularly engages in international conferences on neuromuscular diseases, further raising awareness and discussing the critical unmet medical needs that exist within the patient community.

Commitment to Rare Disease Therapies

Currently, myTomorrows is overseeing more than 20 clinical trial recruitment and EAPs with BioPharma sponsors dedicated to rare diseases. Their expertise extends beyond DMD to other neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease, establishing a reputation as a leader in patient navigation. These ongoing partnerships demonstrate their commitment to paving the way for innovative treatments in the rare disease space.

As highlighted by Terri Ellsworth, a Duchenne patient advocate, the journey toward treatment can be overwhelming without appropriate support. “Without clinical trial participation, we cannot advance progress and innovation in life sciences,” she stated, drawing on her personal connection to the disease. Her son’s participation in a clinical study notably contributed to the first FDA approval for a treatment targeting Duchenne.

Looking Toward the Future

As myTomorrows continues to advance its technology and broaden its reach, they remain committed to supporting the Duchenne community and others facing similar challenges. Celebrating the enrollment of hundreds of patients represents more than just numbers; it embodies the hopes and aspirations of countless families navigating the complexities of rare diseases.

By harnessing cutting-edge technology alongside compassionate support, myTomorrows is not only helping patients find pathways to treatment but is also demonstrating the potential of health technology to transform lives. With a steadfast mission to break down barriers, the company stands ready to lead the charge toward a future where innovative treatments are within reach for all.

For those interested in learning how myTomorrows is working to reduce barriers in patient access to treatment options, visit mytomorrows.com.